Hapten Sciences

Executive Summary

Hapten Sciences is a privately held biopharmaceutical company based in Memphis, Tennessee, founded in 2012. The company operates in the small molecules sector and is dedicated to identifying and efficiently developing novel, early-stage therapeutic candidates that address significant global health needs. By focusing on translating early-stage research into viable products, Hapten Sciences aims to contribute to global well-being through innovative small molecule therapies. Despite being in a relatively early stage, the company's strategic approach positions it to potentially advance promising candidates through preclinical and clinical development. However, with limited public information on its pipeline, financials, or partnerships, the company's near-term outlook remains uncertain.

Upcoming Catalysts (preview)

• TBDAnnouncement of lead candidate entering preclinical development40% success
• TBDSecuring a Series A financing round50% success
• TBDInitiation of a strategic research collaboration35% success